UICC World Cancer Congress 2006

Methods:: Data from two published cohort series and a phase 2 study in advanced cancer had identical dosing schedules and follow up assessments. MP doses were 10 mg/d (5 mg at 8 a.m. and at 12 noon) titrated to a maximum of 30 mg/d. Side effects reported with methylphenidate; (agitation, anorexia, dizziness, dry mouth, headache, insomnia, nausea, palpitations, tremors, vomiting) were assessed for severity. Scores were none (0), mild (1), moderate (2), and severe (3), respectively.

Results: 50 patient, median age of 69 (range 30-90) years were included. Patients received 10 mg/d (N=35) or 20 mg/d (N=13). S/E occurred in 26%, insomnia (14%), nausea (12%), dry mouth (12%), agitation (10%), anorexia (8%), tremors (8%), headache (4%), palpitations (2%), and vomiting (2%). Patients could have more than one S/E. Most (98%) showed improvement in depression and/or fatigue. Mean symptom scores decreased one week after starting MP agitation ƒË0.48„b0.68 to 0.32„b0,55 (Pƒ¬0.029)ƒÍ, anorexia ƒË0.86„b1.00 to 0.67„b0.83 (Pƒ¬0.008)ƒÍ, and dizziness ƒË0.14„b0.40 to 0.06„b0.31 (Pƒ¬0.011)ƒÍ. Treatment with MP in advanced cancer does not produce significant short term adverse effects. Doses are lower than other reports but effective.